Investment House LLC Has $4.32 Million Stake in Solventum Corporation $SOLV

Investment House LLC reduced its stake in Solventum Corporation (NYSE:SOLV) by 18.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 54,511 shares of the company’s stock after selling 12,712 shares during the period. Investment House LLC’s holdings in Solventum were worth $4,319,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SOLV. United Services Automobile Association bought a new stake in Solventum in the first quarter valued at $239,000. Woodline Partners LP increased its stake in Solventum by 40.7% in the first quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock valued at $888,000 after purchasing an additional 3,377 shares in the last quarter. Intech Investment Management LLC increased its stake in Solventum by 167.0% in the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock valued at $1,268,000 after purchasing an additional 10,425 shares in the last quarter. First Trust Advisors LP increased its stake in Solventum by 5.8% in the second quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock valued at $19,546,000 after purchasing an additional 14,151 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in Solventum in the second quarter valued at $766,000.

Insider Buying and Selling at Solventum

In other news, Director Amy Mcbride Wendell acquired 1,475 shares of Solventum stock in a transaction on Tuesday, March 10th. The stock was acquired at an average cost of $68.03 per share, with a total value of $100,344.25. Following the transaction, the director owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.24% of the stock is owned by corporate insiders.

Solventum Trading Down 1.8%

SOLV opened at $74.74 on Wednesday. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. Solventum Corporation has a fifty-two week low of $62.38 and a fifty-two week high of $88.20. The firm has a market capitalization of $12.94 billion, a PE ratio of 9.16, a P/E/G ratio of 1.18 and a beta of 0.59. The company’s 50-day moving average is $68.16 and its 200 day moving average is $74.65.

Solventum (NYSE:SOLV) last posted its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter in the prior year, the business posted $1.34 EPS. The firm’s revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, research analysts predict that Solventum Corporation will post 6.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. BTIG Research reaffirmed a “buy” rating and issued a $89.00 price target on shares of Solventum in a research note on Wednesday, May 6th. Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Mizuho set a $100.00 price target on shares of Solventum and gave the company an “outperform” rating in a research note on Tuesday, January 20th. KeyCorp lifted their price target on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, Stifel Nicolaus decreased their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $84.25.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.